Never miss a detail with enhanced and expanded comprehensive genomic profiling (CGP)
When it comes to cancer, an incomplete picture is an inaccurate picture. Every biomarker reveals unique details that collectively help decipher the genomic landscape of cancer. If you want a holistic view of cancer, comprehensive genomic profiling (CGP) is the way to go. However, emerging targets and evolving guidelines mean adapting assay content can be time-consuming.
Don’t risk missing a key cancer biomarker. Unleash the full potential of comprehensive genomic profiling with QIAseq.
Achieve target enrichment by hybrid capture using QIAseq xHYB CGP Panels:
- Detect 720+ genes, detecting SNVs, Indels, CNVs, MSI, TMB and RNA fusions
- Analyze DNA and RNA biomarkers from a single sample
- Capture challenging regions of interest with high uniformity, including GC-rich regions
- Use with multiple sample types, including FFPE and liquid biopsy samples
- Customize panels or expand coverage and achieve actionable reports in just 4 days
Achieve target enrichment by amplicons using the QIAseq Multimodal Human Pan Cancer Panel:
- Cover 523 DNA gene targets, 56 RNA fusion targets and 26 MSI loci
- Ensure complete coverage of targets with high sensitivity using QIAseq enrichment technology
- Benefit from the only one-day, low-input sample to sequencing workflow for simultaneous profiling of DNA and RNA biomarkers
- Customize content with the QIAseq Multimodal Custom Panels option
QIAseq xHYB CGP Panels are intended for non-clinical applications. QIAseq xHYB CGP Panels are not intended for the diagnosis, prevention, or treatment of a disease.
The QIAseq Multimodal Pan-Cancer Panel is intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.
